THIS SHARE WILL BE WORTH 3.00 IN 2009

Protherics gives CoVaccine's novel adjuvant a shot
By Gregory Roumeliotis.

21/06/2006 - Biopharmaceutical firm Protherics has acquired a new adjuvant from Dutch company CoVaccine that it will use for its hypertension vaccine, hoping to boost antibody production by tenfold.

http://www.in-pharmatechnologist.com/news/ng.asp?n=68578-protherics-angiotensin-covaccine-adjuvant

Very strange, or is it.

Eight what look like test trades go through as buys, totaling 494 shares, then 2 x 1,450,000, out of hour trades mid range go through. Will be interesting to see what they open at tomorrow.

Opened 1.5p higher, and climbed slightly since. Looks like they were buy's.

Not quite as exciting as it could have been though greekman, especially given the positive nature of today's markets.

It looks as if your right. No doubt, unless bad news comes prior to opening today, most shares will open up due to the Dow's close of 217 up. Strange that thing called market sentiment.

Indeed it is. Pity PTI wasn't able to rise again today.

Yes, well that's the way the cookie crumbles ( strange saying, I wonder where it came from ). Well have a good week-end. Night follows day and every cloud etc. Rambling now. Could be old age, the bottle of vino, or both.
Cheers greek.

Cheers to you too greek. Don't let the bed bugs bite!

Another nice rise as at 0900hrs, following on from yesterdays positive move.
Something tells me that within the next couple of trading day we will see an RNS re an institution buying, with some delayed buys showing. The mms appear to be tempting sellers perhaps in order to fill an order. All imho of course.
Whatever the reason for the rise, it is looking good.

looking gooood!

Yes, a good week. More to come?

Looks like M@G have increased their holdings.
On 26/09/06 holdings notified at 10,431,716.
On 25/01/06 holdings notified at 9,873,542.
So a nice increase of 558,174.

Anyone know whats happening.
Prior to 0853 there was only one small trade, a buy of 300 shares.
Since then a rush of buys, and up 3p. OK only 157,000 in total but strange but 18 buys in 8 mins! Could of course be people turning up at work and getting on line, but to my knowledge this does not usually happen, when no news.

Now up 3.75p ?

Post in error

From strength to strength.

AstraZeneca Updates CytoFab(TM) Development Programme.

The Phase II programme will start in the second half of 2007 and is expected to
last up to 21 months. It will be immediately followed by the initiation of the
Phase III study in the US, EU and Japan.

Looking good. The mid to end of 2009 is quit a long way off, but in the drug business it's not too long to wait. Also don't forget PTI's other products in their pipeline.

More delays now...argh


Protherics PLC
03 November 2006

Protherics PLC

AstraZeneca Updates CytoFab(TM) Development Programme

London, UK; Brentwood, TN, US; 3 November 2006 - Protherics PLC ('Protherics' or
the 'Company') and AstraZeneca today announce AstraZeneca's intention to expand
the development plan for CytoFab(TM), a treatment for severe sepsis, with the
addition of a 480 - patient Phase II study programme.

AstraZeneca has recently completed consultations with regulators in the US and
EU. These consultations confirmed that a single Phase III study could be
sufficient for regulatory approval. Furthermore, to meet the regulatory needs
of both agencies, it is required that AstraZeneca implement a Phase II study
programme to support the single global Phase III study.

Data from Phase II will be used to more accurately estimate the number of
patients required, and confirm the appropriate dose for the Phase III study, as
well as providing further supporting efficacy and safety data. This may enable a
shorter timetable for the Phase III programme than originally anticipated by
AstraZeneca.

The Phase II programme will start in the second half of 2007 and is expected to
last up to 21 months. It will be immediately followed by the initiation of the
Phase III study in the US, EU and Japan.

Under the terms of the licensing agreement, AstraZeneca is responsible for
conducting and funding the global development of CytoFab(TM) and Protherics is
responsible for product supply.

John Rex, Vice-President, Medical Director for Infection, AstraZeneca, said:

'Our goal is to optimise the chances of showing a statistically and clinically
meaningful result with CytoFab(TM), in a single, global Phase III study, while
ensuring an acceptable time to market. To increase the likelihood of success in
this complex disease and reflecting the changing regulatory environment for
biologics, we have made the decision to undertake additional clinical work. We
hope that this will help to reduce the size of and the time needed to complete
the Phase III study. We believe that this development plan will give us the best
chance of successful registration for this exciting treatment.'

Andrew Heath, Chief Executive of Protherics, said:

'CytoFab(TM) represents a major market opportunity and AstraZeneca's proposed
development programme provides the treatment with the best route to
registration. We now have a clear view of the steps needed to make this
important new treatment available to sepsis patients worldwide.'


| Ends |

Opened lower as the MM's knew that most punters would look at it as more delay, but it's not bad news. The drug industry is not a get rich today, tomorrow or even next year.
Patience is the key. Protherics must be one of the best up and coming companies in it's field. If things progress as expected, todays sp will be looked back on as a fantastic bargain. It also as stated has other products progressing nicely.

Following is an extract from a Market-wire. CytoFab, Voraxase, Prolarix, CroFab, (pit viper antivenom) and DigiFab are also mentioned.

CytoFab is a first in class anti-TNF-alpha polyclonal antibody fragment (Fab) product, which is being developed for the treatment of severe sepsis.

The most advanced products in the Company's portfolio are Voraxaze, which is expected to be approved in the US and EU in 2007, subject to regulatory reviews, as an intervention when methotrexate blood levels remain dangerously high following high doses for the treatment of cancer and CytoFab, which is being developed by AstraZeneca, initially for severe sepsis, and is expected to start an additional Phase II study in 2007.

See link for full article, it's well worth a read to reiterate what a forward looking company Protherics is.

If I had spare cash, I would be looking at this drop in the sp as a buy opportunity.

http://www.marketwire.com/mw/release_html_b1?release_id=180059

Iam glad that Iam not the only person who has overspent on s.e.o so have no money left to buy these at this price /Ihope we have done the right thing///

Protherics to resubmit its Voraxaze(TM) BLA following FDA data request.
Still looking good for Voraxaze, but any delay is bad news even if it appears to be only 6 months (a small time in the drug world).
This looks worse than it is probably due to being on the back of the previous RNS.
Shares look a good buy at this price, as long as a term of at least 1 to 2 years is being looked at.